Kılıç, Mehmet AÖzdemir, Gül NihalTahtakesen, Tuba NurGökçe, Müge G.Uysalol, Ezgi PaslıBayram, CengizAyçiçek, AliAydo?an, Gönül2021-06-162021-06-162021Kiliç, M. A., Özdemir, G. N., Tahtakesen, T. N., Gökçe, M., Uysalol, E. P., Bayram, C., ... & Aydoğan, G. (2021). Clinical Features and Outcome of Children With Hereditary Spherocytosis. Journal of Pediatric Hematology/oncology.1077-4114https://doi.org/10.1097/MPH.0000000000002211https://hdl.handle.net/20.500.12713/1800Objective: The aim of this study was to evaluate the demographics, clinical, and laboratory findings and treatment responses of patients with hereditary spherocytosis (HS). Materials and Methods: Data of children with HS were examined. Diagnosis was based on clinical history, physical examination, family history, presence of spherocytes on peripheral blood smear, and osmotic fragility test. Results: A total of 101 patients were included. The median (range) age at diagnosis was 38.0 (1 to 188) months. Mild, moderate, and severe forms of HS were present in 29 (28.7%), 15 (14.9%), and 57 (56.4%) patients, respectively. Family history was available in 73 patients and 56 of these (76.7%) had a positive family history for HS. Forty-five (44.5%) patients needed regular transfusions and all of these had severe disease. Although most patients did not require transfusion postsplenectomy, 2 of 45 (4.4%) patients continued to require transfusion. Transfusion dependence was significantly (P<0.001) higher in patients with severe spherocytosis. Conclusions: In HS, splenomegaly, pallor, and jaundice are the most common clinical features. Splenectomy dramatically reduces hemolysis in most cases and virtually abolishes further requirement for transfusion.eninfo:eu-repo/semantics/closedAccessChildrenHemolytic AnemiaHereditary SpherocytosisSplenectomyArticle34054043WOS:0007603913000122-s2.0-85107450404Q410.1097/MPH.0000000000002211Q3